HROW: Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for HROW
Across the 9 sessions after earlier HROW headlines, the stock closed higher 5 times and lower 4 times, with a median move of 5.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HROW | SPY |
|---|---|---|---|
| Mar 3, 2026 | Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance | -28.0% | -0.9% |
| Feb 18, 2026 | Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 | -1.3% | +0.5% |
| Feb 17, 2026 | Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits | +6.0% | +0.2% |
| Feb 3, 2026 | OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California | +5.1% | -0.8% |
| Feb 2, 2026 | Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth | +9.7% | +0.5% |
| Nov 24, 2025 | Harrow to Present at Two Investor Conferences in December | +0.2% | +1.5% |
Quantisnow market dataNASDAQ
HROW
Harrow Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for HROW
Full HROW profile on Quantisnow Follow HROW and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time